OTCMKTS:NWPHF Newron Pharmaceuticals (NWPHF) Stock Price, News & Analysis → Urgent: Protect Your Investments from a Chinese Invasion (From Behind the Markets) (Ad) Free NWPHF Stock Alerts $8.52 0.00 (0.00%) (As of 03/27/2024 ET) Add Compare Share Share Today's Range$8.52▼$8.5250-Day Range$8.52▼$8.5252-Week Range$5.22▼$8.55VolumeN/AAverage Volume1,525 shsMarket Capitalization$152.08 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartHeadlinesShort InterestStock AnalysisChartHeadlinesShort Interest Get Newron Pharmaceuticals alerts: Email Address Ad Behind the MarketsUrgent: Protect Your Investments from a Chinese InvasionAn alarming new reality is unfolding across America. The United States is bracing for the unthinkable - a potential Chinese invasion.Click here to get my exclusive report NOW >>> About Newron Pharmaceuticals Stock (OTCMKTS:NWPHF)Newron Pharmaceuticals S.p.A., a biopharmaceutical company, focus on the development of novel therapies for the treatment of central nervous system (CNS) and pain in Italy and the United States. It offers Xadago (safinamide), a chemical entity for the treatment of Parkinson's in the European Union, Switzerland, the United Kingdom, the United States of America, Australia, Canada, Latin America, Israel, the United Arab Emirates, Japan, and South Korea. The company's product pipeline includes Evenamide, an add-on therapy for the treatment of Schizophrenia and treatment-resistant schizophrenia which is in Phase III clinical trial; and Ralfinamide for the treatment of rare neuropathic pain indication. In addition, it has a strategic partnership with Zambon for the commercialization of safinamide; and license agreement with Meiji Seika Pharma Co., Ltd., for research, develop, manufacture, and marketing of safinamide. The company was founded in 1999 and is headquartered in Bresso, Italy.Read More NWPHF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NWPHF Stock News HeadlinesMarch 19, 2024 | finance.yahoo.comNewron Presents 2023 Financial Results and Provides 2024 OutlookMarch 15, 2024 | finance.yahoo.comNewron announces agreement with the European Investment Bank (EIB) to extend the near-term tranche repayment dates of its 2018 financing agreementMarch 28, 2024 | Behind the Markets (Ad)Urgent: Protect Your Investments from a Chinese InvasionAn alarming new reality is unfolding across America. The United States is bracing for the unthinkable - a potential Chinese invasion.March 13, 2024 | finance.yahoo.comBreakeven Is Near for Newron Pharmaceuticals S.p.A. (VTX:NWRN)January 4, 2024 | finance.yahoo.comNewron Reports Exceptional One-year Results of Study 014/15 With Evenamide in Treatment-resistant Schizophrenia (TRS)January 2, 2024 | msn.comNewron enrols all subjects in schizophrenia treatment trialDecember 29, 2023 | markets.businessinsider.comEQS-News: Newron completes enrollment of schizophrenia patients in potentially pivotal study 008A with EvenamideDecember 13, 2023 | morningstar.comNewron Pharmaceuticals SpA NWRNMarch 28, 2024 | Behind the Markets (Ad)Urgent: Protect Your Investments from a Chinese InvasionAn alarming new reality is unfolding across America. The United States is bracing for the unthinkable - a potential Chinese invasion.October 9, 2023 | finance.yahoo.comNewron TRS Study 6 Months’ Results: Evenamide Substantially Improves Patients to an Extent That They No Longer Meet Protocol Entry CriteriaOctober 4, 2023 | businesswire.comNewron to Present Three Posters on Its Clinical Program Evaluating Evenamide in the Treatment of Schizophrenia at the 36 th European College of Neuropsychopharmacology CongressOctober 4, 2023 | finance.yahoo.comNewron to Present Three Posters on Its Clinical Program Evaluating Evenamide in the Treatment of Schizophrenia at the 36th European College of Neuropsychopharmacology CongressOctober 2, 2023 | markets.businessinsider.comEQS-News: Newron appoints Margarita Chavez as board advisorOctober 2, 2023 | finance.yahoo.comNewron Appoints Margarita Chavez as Board AdvisorAugust 4, 2023 | finance.yahoo.comNewron Announces H1 2023 Results and Provides R&D UpdateAugust 4, 2023 | markets.businessinsider.comEQS-News: Newron announces H1 2023 results and provides R&D updateJune 15, 2023 | finance.yahoo.comInvesting in Newron Pharmaceuticals (VTX:NWRN) a year ago would have delivered you a 187% gainMay 2, 2023 | markets.businessinsider.comEQS-News: Newron announces Senior Management Team changesMay 2, 2023 | uk.finance.yahoo.comNewron announces Senior Management Team changesApril 27, 2023 | finance.yahoo.comAnalysts Expect Newron Pharmaceuticals S.p.A. (VTX:NWRN) To Breakeven SoonApril 18, 2023 | uk.finance.yahoo.comNewron announces AGM 2023 resultsApril 18, 2023 | markets.businessinsider.comEQS-News: Newron announces AGM 2023 resultsMarch 28, 2023 | markets.businessinsider.comEQS-News: Newron presents six-month interim data from the first 100 patients randomized in study 014/015 at the 31st European Congress of PsychiatryMarch 28, 2023 | uk.finance.yahoo.comNewron presents six-month interim data from the first 100 patients randomized in study 014/015 at the 31st European Congress of PsychiatryMarch 17, 2023 | markets.businessinsider.comEQS-News: Newron to present at the 31st European Congress of PsychiatryMarch 14, 2023 | uk.finance.yahoo.comNewron announces 2022 financial results and provides outlook for 2023February 13, 2023 | msn.comNewron: Managing India’s Next-gen of Modern SchoolsSee More Headlines Receive NWPHF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Newron Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today3/28/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolOTCMKTS:NWPHF CUSIPN/A CIKN/A Webwww.newron.com Phone(902) 610-3461Fax39-02-6103-4654Employees23Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$6.82 million Price / Sales22.30 Cash FlowN/A Price / Cash FlowN/A Book Value$0.21 per share Price / Book40.57Miscellaneous Outstanding Shares17,850,000Free FloatN/AMarket Cap$152.08 million OptionableNot Optionable Beta0.53 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesMr. Stefan Weber (Age 59)CEO & Executive Director Comp: $465.59kMr. Roberto GalliVice President of FinanceMr. Filippo MoriggiaVice President of OperationsDr. Ravi Anand (Age 67)Chief Medical Officer Comp: $1.1MKey CompetitorsI-MabNASDAQ:IMABElite PharmaceuticalsOTCMKTS:ELTPSpyre TherapeuticsNASDAQ:SYRELifecore BiomedicalNASDAQ:LFCRNuvectis PharmaNASDAQ:NVCTView All Competitors NWPHF Stock Analysis - Frequently Asked Questions How have NWPHF shares performed in 2024? Newron Pharmaceuticals' stock was trading at $5.22 on January 1st, 2024. Since then, NWPHF shares have increased by 63.2% and is now trading at $8.52. View the best growth stocks for 2024 here. Are investors shorting Newron Pharmaceuticals? Newron Pharmaceuticals saw a increase in short interest in the month of March. As of March 15th, there was short interest totaling 29,600 shares, an increase of 60.0% from the February 29th total of 18,500 shares. Based on an average daily volume of 0 shares, the short-interest ratio is currently ∞ days. View Newron Pharmaceuticals' Short Interest. How do I buy shares of Newron Pharmaceuticals? Shares of NWPHF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:NWPHF) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeAI to Meet the Same Fate as EVs? Porter & CompanyGrab Your Free Bitcoin Today!Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Newron Pharmaceuticals S.p.A. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.